Drug Profile


Alternative Names: GRT-6005

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Grunenthal
  • Developer Allergan; Grunenthal
  • Class Cyclohexylamines; Indoles; Opioid analgesics; Small molecules; Spiro compounds
  • Mechanism of Action Nociceptin receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cancer pain
  • Phase II Back pain; Diabetic neuropathies; Musculoskeletal pain
  • No development reported Postoperative pain

Most Recent Events

  • 30 Sep 2016 Efficacy and adverse events data from a phase III trial in Cancer pain released by Grunenthal
  • 16 Sep 2016 Pharmacodynamics data from a preclinical study in Pain presented at the 16th World Congress on Pain (WCP-2016)
  • 01 May 2016 Grünenthal completes the phase III CORAL XT extension trial for Cancer pain in Austria, Belgium, Denmark, Germany, Hungary, Poland, Romania, Serbia, Slovakia, Sweden, the UK, Spain, Bulgaria, the Netherlands and Croatia (NCT02031432, EudraCT2013-001877-26)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top